Drug
Medi4736
Medi4736: highest development phase Phase 2, developed by AstraZeneca. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- AstraZeneca
Trials
| Drug | Phase | Indication |
|---|---|---|
| MEDI4736 NCT02669914 | Phase 2 | Non-Small Cell Lung Cancer |
Latest
No recent events.
Follow Medi4736 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.